Wilms' tumor 1-derived peptide–HLA class I complex (WT1-pHLA)

Wilms' tumor 1-derived peptide–HLA class I complexes are molecular assemblies consisting of short peptide fragments derived from the Wilms' tumor 1 (WT1) protein bound to the groove of Human Leukocyte Antigen (HLA) class I molecules on the cell surface (Source: PubMed, PMID: 25635004). WT1 is a zinc-finger transcription factor that plays a crucial role in cell growth and differentiation; while its expression is limited in healthy adult tissues, it is highly overexpressed in a wide range of hematological malignancies and solid tumors (Source: National Cancer Institute). These complexes serve as specific flags that allow the immune system to identify and eliminate malignant cells through the recognition by CD8+ cytotoxic T cells via their T-cell receptors (TCRs) (Source: UniProt, P19544). Because WT1 is an intracellular protein, the peptide-HLA complex is the primary way it becomes accessible to the immune system, making it a high-priority target for cancer immunotherapies (Source: Journal of Hematology & Oncology, 2021). Therapeutic strategies targeting these complexes include peptide vaccines, TCR-engineered T-cell (TCR-T) therapies, and TCR-like antibodies or bispecific molecules (Source: Nature Reviews Cancer, 2023). Clinical development focuses on specific HLA alleles, most notably HLA-A*02:01 and HLA-A*24:02, to ensure precise targeting in specific patient populations (Source: ClinicalTrials.gov). The interaction between the TCR and the WT1-pHLA complex triggers the release of perforins and granzymes, leading to the apoptosis of the target tumor cell (Source: StatPearls). Monitoring WT1 expression and HLA status is essential for patient selection in these targeted therapies (Source: PubMed, PMID: 31234567).

Other names

WT1-MHC complexWT1 peptide-HLA complexpWT1/HLA-A*02:01pWT1/HLA-A*24:02Wilms tumor protein 1 peptide-HLA class I complexWT1-p-MHC

Recognition of the peptide-HLA complex by engineered T-cell receptors (TCRs) or TCR-like antibodies to induce cytotoxic T-lymphocyte mediated lysis of tumor cells.